Skip to content
Physician talking to a patient

Elevating the Vision for BPH Treatment

Durability + Patient Experience​

The UroLift™ System is a market leader and proven minimally invasive treatment for benign prostatic hyperplasia (BPH) that provides an alternative to BPH medications and major surgery.1,2  It is supported by over a decade of clinical evidence.

Read Latest Published Study

A proven earlier treatment alternative to BPH medications2

The only leading BPH minimally invasive surgical therapy (MIST) with consistent durability in the real-world and clinical trials2,3

A safe, effective treatment,2 providing a superior patient experience* among leading BPH procedures3-5​

One of the most studied BPH MIST procedures with 145+ peer reviewed and clinical publications

A Proven Earlier Treatment Alternative to Medications2

98%

of men seeing a doctor for BPH are treated with medications or watchful waiting1

Medications like alpha blockers, 5-ARIs or combination therapy are first-line treatment for patients with BPH symptoms, but they come with some significant tradeoffs.​

  • Maximum median IPSS score reduction for common BPH medications is only 7 points while placebo provided 4-point improvement at 4 years6
  • Lifelong treatment and side effects7-16
  • Low compliance17
  • Long-term use of BPH medication may lead to bladder dysfunction18

New Data:

The IMPACT Study

This study represents the largest head-to-head RCT comparing efficacy, safety and patient experience* after UroLift™ PUL and medical therapy (alpha blocker Tamsulosin).29 Preliminary data suggest that UroLift™ PUL yields advantages in the first three months:

  • Better symptom relief and quality of life improvements29
  • Higher patient satisfaction and goal attainment29
  • More improvements in daily activities29
Graph showing IPSS Total Scores Through 3 Months

UroLift™ System PUL patients experienced improvements of 8.6 and 10 in IPSS total score at 1 and 3 months, respectively, compared to 3.4 and 3.1 for medication.29

Graph showing Quality-of-Life Scores Through 3 Months

UroLift™ System PUL QoL scores improved 2.0 (39.3%) and 2.2 (47.9%) vs. 0.6 (10.2%) and 0.5 (7.8%) for medication at 1 and 3 months.29

Despite technological innovation, only 2% of men seeing a doctor for BPH are treated with a surgical intervention1​

Traditional invasive surgery like TURP has been the gold standard BPH treatment since the 1920's. Newer technology has been introduced over the years to help improve patient experience factors such as long-term recovery, post-op complications and ejaculatory dysfunction.

Simplified UroLift logo

UroLift™ System

Market leading minimally invasive BPH procedure1

Grade 3+ or Serious Adverse Events:

0.7%2

—

Sexual Function:

0% EjD**2

Icon of a scalpel

TURP

Traditional invasive surgery since 1926

Grade 3+ or Serious Adverse Events:

7.619-20

–

Sexual Function:

36% EjD**19-20

Icon of a waterjet

Aquablation

Robotic waterjet ablation comparable to traditional invasive surgeries

Grade 3+ or Serious Adverse Events​:

6.9%19-20

— 

Sexual Function:

10% EjD**19-20

The graphic is for educational purposes only. Direct comparisons of studies cannot be made.

**De novo ED or EjDamong sexually active men

1 in 20​

Did you know? New data shows that within one year of BPH surgery, 1 in 20 patients may require retreatment regardless of the procedure type.3​

Real-World Durability Analysis

Note: This webinar counts toward continuing education requirements for the UroLift™ System Center of Excellence program. To receive credit for watching the webinar, please view in UroLift University.

The Only Leading BPH MIST With Consistent Durability in Real World and Clinical Trials2,3

In a recent real-world analysis, the ​UroLift™ System demonstrated a comparable 5-year retreatment rate to the rate shown in the L.I.F.T. RCT (11.6% and 13.6%).2,3

Across clinical trials and real-world studies, the UroLift™ System has demonstrated largely consistent IPSS outcomes.2,21

5-year surgical retreatment rate vs. L.I.F.T. RCT surgical retreatment rate2,3

L.I.F.T. is 13.6% and Healthcare Claims and Utilization Study is 11.6%

Provides Superior Patient Experience*
Among Leading BPH Procedures3-5​

Icon of a health symbol

Rapid relief with a low risk profile22-23​

Icon of a catheter

Lowest catheter rate of the leading BPH procedures2,23-27

Icon of a shield

Preservation of sexual function***2​

Patient Safety

Once procedure volume is factored in, the UroLift™ System has the lowest rates of mild, moderate, and severe complications on a per case basis from 2019-202228

The UroLift™ System had the lowest post-procedural complication rate at one year compared to other procedures.3

MAUDE Study: Patient Safety

Note: This webinar counts toward continuing education requirements for the UroLift™ System Center of Excellence program. To receive credit for watching the webinar, please view in UroLift University.

Learn More About the UroLift™ System Procedure and the Latest Data

References

  • 1. U.S. 2022 estimates based on US Market Model 2022-24 (5-17-22 FINAL), which is in part based on Symphony Health PatientSource® 2018-21, as is and with no representations/ warranties, including accuracy or completeness.

  • 2. Roehrborn, Can J Urol 2017

  • 3. Kaplan, Prostate Cancer Prostatic Dis 2023

  • 4. Gratzke, BJU Int 2016

  • 5. Tutrone, Can J Urol 2020

  • 6. McConnell, NEJM 2003

  • 7. AUA BPH Guidelines, 2003, 2010

  • 8. Chang DF, Campbell JR, J Cataract Refract Surg. 2005 Apr; 31(4): 664-673

  • 9. Lai et al, CMAJ. 2016 Mar 01; 188(4): 255-260

  • 10. Duan et al, Pharmacoepidemiol Drug Saf. 2018 Mar; 27(3): 340-348

  • 11. Welk et al, JAMA Intern Med. 2017 May 1; 177(5): 683-691

  • 12. Traish et al, Horm Mol Biol Clin Investig. 2017 Jun 21; 30(3): 1-16

  • 13. Wei et al, BMJ. 2019 Apr 10; 365:I12049

  • 14. Welk et al, J Neurol Sci. 2017 Aug 15; 379: 109-111

  • 15. S. Diviccaro, et al. Neurobiology of Stress 12 2020

  • 16. Lusty, J Urol 2021

  • 17. Cindolo, Eur Urol 2015

  • 18. Young et al. The Changing Practice of Transurethral Resection of the Prostate, Ann. R. Coll Surg England, 2018

  • 19. Gilling, Can J Urol 2022

  • 20. Gilling, J Urol 2018

  • 21. Eure, J Endourol 2019

  • 22. Roehrborn, J Urol 2013

  • 23. Shore, Can J Urol 2014

  • 24. Bachmann, Eur Urol 2013

  • 25. McVary, J Urol 2016

  • 26. Mollengarden, Prostate Cancer Prostatic Dis 2018

  • 27. Das, Can J Urol 2019

  • 28. Shinghal R, Ashley M, Eure G (2023). Total Procedural Context is Crucial in Understanding BPH Treatment Device Safety in the FDA’s MAUDE Database. (Manuscript in preparation)

  • 29. Roehrborn, et al, AUA 2024. Preliminary RCT Analysis of Minimally Invasive Surgery vs. Medication in the Initial Treatment of BPH-Associated LUTS. AUA Study sponsored by Teleflex Incorporated or its affiliates.

  • *Patient experience defined as a combination of rapid symptom relief, low risk profile, and preservation of sexual function

  • **De novo ED or EjD among sexually active men

  • ***No instances of new, sustained erectile or ejaculatory dysfunction in the L.I.F.T. pivotal study

  • +While the MAUDE Database is a powerful resource, it is subject to certain limitations. These include the potential for underreporting of adverse events and the variability in the quality and consistency of the information reported. MAUDE data does not represent all known safety information for a reported medical device and should be interpreted in the context of other available information when making device-related or treatment decisions.

MAC02843-01 Rev A​